Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

603
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
603

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Corrigendum to "Ginsenoside Rg1 mitigates sepsis-associated acute respiratory distress syndrome by promoting autophagy through the Prdx1-PTEN/PI3K/AKT pathway" [Phytomedicine Volume 154, May 2026, 158027].

Phytomedicine : international journal of phytotherapy and phytopharmacology·2026
Same author

Ginsenoside Rg1 mitigates sepsis-associated acute respiratory distress syndrome by promoting autophagy through the Prdx1-PTEN/PI3K/AKT pathway.

Phytomedicine : international journal of phytotherapy and phytopharmacology·2026
Same author

Phospholipase A2 and Systemic-Immune Inflammation Index as Early Predictors of Neurotoxicity Induced by Acute Glufosinate Ammonium Poisoning: A Population-Based Case-Control Analysis.

Emergency medicine international·2026
Same author

Global, regional, and national burden of intracerebral hemorrhage and attributable risk factors in youths and young adults, 1990-2021: a statistical analysis of incidence, mortality, and DALYs.

Frontiers in neurology·2025
Same author

Study of the Solid Solubility Limit and Growth of Cd<sub>1-<i>x</i></sub>Mn<sub><i>x</i></sub>Te Multicomponent Single Crystals for Miniaturized Magneto-Optical Isolators.

Inorganic chemistry·2025
Same author

The association between enema and nervous system injury in Diquat poisoning.

Scientific reports·2025

Related Experiment Video

Updated: Jan 8, 2026

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

13.1K

Ceftazidime-Induced Agranulocytosis: A Case Report.

Bingbin Dong1,2, Xin Wu1,3, Changbao Huang1

  • 1Department of Emergency Medicine Yijishan Hospital, First Affiliated Hospital of Wannan Medical College Wuhu China.

Clinical Case Reports
|December 19, 2025
PubMed
Summary

Ceftazidime can rarely cause severe agranulocytosis, a dangerous drop in white blood cells. Promptly stopping the drug and using G-CSF can help patients recover.

Keywords:
adverse drug reactionagranulocytosisceftazidimedrug safetyneutropenia

More Related Videos

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

810

Related Experiment Videos

Last Updated: Jan 8, 2026

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

13.1K
Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

810

Area of Science:

  • Pharmacology
  • Hematology
  • Internal Medicine

Background:

  • Ceftazidime is a common antibiotic.
  • Adverse events typically include hypersensitivity and gastrointestinal issues.
  • Neutropenia is a rare complication.

Purpose of the Study:

  • To report a rare case of ceftazidime-induced agranulocytosis.
  • To highlight the importance of considering drug-induced cytopenia.

Main Methods:

  • Case presentation of an 89-year-old woman.
  • Clinical assessment, imaging, and laboratory tests.
  • Exclusion of other causes of neutropenia.

Main Results:

  • Patient developed severe neutropenia and agranulocytosis during ceftazidime treatment.
  • Cessation of ceftazidime and administration of G-CSF led to hematological recovery.
  • Other causes for cytopenia were ruled out.

Conclusions:

  • Ceftazidime can induce agranulocytosis, though rarely.
  • Clinicians must consider drug-induced cytopenia in differential diagnosis.
  • Early drug cessation and G-CSF are crucial for recovery.